Patents Assigned to G1 Therapeutics, Inc.
  • Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
    Patent number: 10865210
    Abstract: This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 15, 2020
    Assignee: G1 Therapeutics, Inc.
    Inventors: Alexander Smith, Hannah S. White, Francis Xavier Tavares, Sergiy Krasutsky, Jian-Xie Chen, Roberta L. Dorrow, Hua Zhong
  • HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS
    Publication number: 20200345743
    Abstract: This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
    Type: Application
    Filed: July 10, 2020
    Publication date: November 5, 2020
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY
    Publication number: 20200345742
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Application
    Filed: May 28, 2020
    Publication date: November 5, 2020
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION
    Publication number: 20200331925
    Abstract: This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
    Type: Application
    Filed: July 1, 2020
    Publication date: October 22, 2020
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, David Jung
  • ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS
    Publication number: 20200283406
    Abstract: This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 10, 2020
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, Ricky D. Gaston, Robert C. Gadwood
  • CDK INHIBITORS
    Publication number: 20200277300
    Abstract: Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: May 13, 2020
    Publication date: September 3, 2020
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay Copeland Strum
  • PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER
    Publication number: 20200239486
    Abstract: This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
    Type: Application
    Filed: April 13, 2020
    Publication date: July 30, 2020
    Applicant: G1 Therapeutics, Inc.
    Inventor: Jay Copeland Strum
  • Highly active anti-neoplastic and anti-proliferative agents
    Patent number: 10709711
    Abstract: This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 14, 2020
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS
    Publication number: 20200216406
    Abstract: This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 9, 2020
    Applicant: G1 Therapeutics, Inc.
    Inventor: Jay Copeland Strum
  • CDK inhibitors
    Patent number: 10696682
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: June 30, 2020
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay Copeland Strum
  • Antiproliferative pyrimidine-based compounds
    Patent number: 10654831
    Abstract: This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 19, 2020
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, Ricky D. Gaston, Robert C. Gadwood
  • Benzothiophene estrogen receptor modulators
    Patent number: 10633362
    Abstract: This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 28, 2020
    Assignee: G1 Therapeutics, Inc.
    Inventor: Jay Copeland Strum
  • MORPHIC FORMS OF G1T38 AND METHODS OF MANUFACTURE THEREOF
    Publication number: 20200123168
    Abstract: This invention provides an unexpectedly stable, highly crystalline form of the di-HCl salt of 2?-((5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one for advantageous therapeutic pharmaceutical efficacy and dosage form stability.
    Type: Application
    Filed: December 19, 2019
    Publication date: April 23, 2020
    Applicant: G1 Therapeutics, Inc.
    Inventors: Alexander Smith, Hannah S. White, Patrica Andres, Xufeng Sun, Lei Zhu, Petinka I. Vlahova
  • Pyrimidine-based compounds for the treatment of cancer
    Patent number: 10618905
    Abstract: This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 14, 2020
    Assignee: G1 Therapeutics, Inc.
    Inventor: Jay Copeland Strum
  • TREATMENT OF EGFR-DRIVEN CANCER WITH FEWER SIDE EFFECTS
    Publication number: 20190374545
    Abstract: The present invention provides methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI to delay or reverse acquired resistance to previously administered EGFR-TKIs. In addition, methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI are provided wherein an intrinsically EGFR-TKI resistant EGFR-mutant cancer is sensitized to the effects of the EGFR-TKI.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 12, 2019
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jessica A. Sorrentino, Jay Copeland Strum, John E. Bisi, Andrew Beelen
  • COMBINATION THERAPY FOR TREATMENT OF CANCER
    Publication number: 20190321332
    Abstract: Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular proliferation, including a cancer or a tumor.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 24, 2019
    Applicants: G1 Therapeutics, Inc., The Board of Trustees of the University of Illinois
    Inventors: JAY C. STRUM, Gregory R. Thatcher, Rui Xiong, Jiong Zhao, Debra A. Tonetti
  • PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS
    Publication number: 20190321370
    Abstract: The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.
    Type: Application
    Filed: June 5, 2019
    Publication date: October 24, 2019
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jessica A. Sorrentino, Ann Y. Lai, Jay C. Strum, Patrick Joseph Roberts
  • HSPC-sparing treatments for Rb-positive abnormal cellular proliferation
    Patent number: 10434104
    Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: October 8, 2019
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors
    Patent number: 10413547
    Abstract: This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: September 17, 2019
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino
  • Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation
    Patent number: 10376519
    Abstract: This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: August 13, 2019
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Ricky D. Gaston, Robert C. Gadwood